Inogen Inc (NASDAQ:INGN)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $62.18 and last traded at $62.75, with a volume of 2570 shares traded. The stock had previously closed at $63.70.

A number of research analysts have issued reports on INGN shares. BidaskClub lowered shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, June 27th. JPMorgan Chase & Co. increased their target price on shares of from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the stock an “overweight” rating in a research report on Wednesday, July 3rd. Needham & Company LLC upgraded shares of Smart Global from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a research report on Friday, June 28th. Finally, Stifel Nicolaus upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from $11.00 to $17.00 in a research report on Wednesday, May 8th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Inogen presently has an average rating of “Hold” and an average price target of $117.60.

The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.70 and a current ratio of 7.35. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of 27.03, a price-to-earnings-growth ratio of 2.60 and a beta of 1.45. The company has a 50-day moving average of $66.39.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, May 7th. The medical technology company reported $0.24 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.05). The firm had revenue of $90.20 million for the quarter, compared to analyst estimates of $89.69 million. Inogen had a return on equity of 15.59% and a net margin of 12.56%. The business’s revenue was up 14.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.48 EPS. On average, equities analysts expect that Inogen Inc will post 1.63 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. bought a new position in Inogen in the 1st quarter valued at approximately $25,000. Hanson McClain Inc. bought a new position in Inogen in the 1st quarter valued at approximately $50,000. Advisor Group Inc. lifted its stake in Inogen by 210.0% in the 4th quarter. Advisor Group Inc. now owns 992 shares of the medical technology company’s stock valued at $123,000 after purchasing an additional 672 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Inogen by 30.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,113 shares of the medical technology company’s stock valued at $138,000 after purchasing an additional 258 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new position in Inogen in the 1st quarter valued at approximately $163,000. 98.61% of the stock is owned by institutional investors and hedge funds.

Inogen Company Profile (NASDAQ:INGN)

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

See Also: What is a capital gains distribution?

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.